Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction
Authors
Keywords
-
Journal
JAMA Network Open
Volume 4, Issue 7, Pages e2114501
Publisher
American Medical Association (AMA)
Online
2021-07-28
DOI
10.1001/jamanetworkopen.2021.14501
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy
- (2020) Dhruv S. Kazi et al. CIRCULATION
- Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018
- (2020) Inmaculada Hernandez et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
- (2020) Mark C. Petrie et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials
- (2020) Muthiah Vaduganathan et al. LANCET
- 271-OR: ADA Presidents’ Select Abstract: Effect of Dapagliflozin on the Incidence of Diabetes: A Prespecified Exploratory Analysis from DAPA-HF
- (2020) SILVIO E. INZUCCHI et al. DIABETES
- Cost-effectiveness of dapagliflozin in chronic heart failure: an analysis from the Australian healthcare perspective
- (2020) Feby Savira et al. European Journal of Preventive Cardiology
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Health Opportunity Cost Threshold for Cost-Effectiveness Analysis in the United States
- (2020) David J. Vanness et al. ANNALS OF INTERNAL MEDICINE
- Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF
- (2020) Silvio E. Inzucchi et al. DIABETES CARE
- Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
- (2020) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessment of National Coverage and Out-of-Pocket Costs for Sacubitril/Valsartan Under Medicare Part D
- (2019) Colette DeJong et al. JAMA Cardiology
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Dapagliflozin on Symptoms, Function and Quality of Life in Patients with Heart Failure and Reduced Ejection Fraction: Results from the DAPA-HF Trial
- (2019) Mikhail N. Kosiborod et al. CIRCULATION
- Why Are We Failing to Address the Issue of Access to Insulin? A National and Global Perspective
- (2018) David Beran et al. DIABETES CARE
- Medical Therapy for Heart Failure With Reduced Ejection Fraction
- (2018) Stephen J. Greene et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Association of the Hospital Readmissions Reduction Program With Mortality Among Medicare Beneficiaries Hospitalized for Heart Failure, Acute Myocardial Infarction, and Pneumonia
- (2018) Rishi K. Wadhera et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- PCSK9 Inhibitors
- (2017) Mark A. Hlatky et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nationwide Coverage and Cost-Sharing for PCSK9 Inhibitors Among Medicare Part D Plans
- (2017) Dhruv S. Kazi et al. JAMA Cardiology
- Cost-Effectiveness of Sacubitril–Valsartan in Patients With Heart Failure With Reduced Ejection Fraction
- (2016) Alexander T. Sandhu et al. ANNALS OF INTERNAL MEDICINE
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
- (2016) Piotr Ponikowski et al. EUROPEAN HEART JOURNAL
- Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses
- (2016) Gillian D. Sanders et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Quantifying the Utility of Taking Pills for Cardiovascular Prevention
- (2015) R. Hutchins et al.
- Professional Fee Ratios for US Hospital Discharge Data
- (2015) Cora Peterson et al. MEDICAL CARE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Quantifying the Utility of Taking Pills for Cardiovascular Prevention
- (2015) R. Hutchins et al. Circulation-Cardiovascular Quality and Outcomes
- ACC/AHA Statement on Cost/Value Methodology in Clinical Practice Guidelines and Performance Measures
- (2014) Jeffrey L. Anderson et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
- (2014) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Post-Hospital Syndrome — An Acquired, Transient Condition of Generalized Risk
- (2013) Harlan M. Krumholz NEW ENGLAND JOURNAL OF MEDICINE
- Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement
- (2013) Don Husereau et al. VALUE IN HEALTH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now